CN102229557A - Semihydrate crystal of silodosin, preparation method thereof and medicinal composition containing semihydrate crystal - Google Patents
Semihydrate crystal of silodosin, preparation method thereof and medicinal composition containing semihydrate crystal Download PDFInfo
- Publication number
- CN102229557A CN102229557A CN2010102453370A CN201010245337A CN102229557A CN 102229557 A CN102229557 A CN 102229557A CN 2010102453370 A CN2010102453370 A CN 2010102453370A CN 201010245337 A CN201010245337 A CN 201010245337A CN 102229557 A CN102229557 A CN 102229557A
- Authority
- CN
- China
- Prior art keywords
- crystal
- silodosin
- organic solvent
- semihydrate
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 40
- PNCPYILNMDWPEY-QGZVFWFLSA-N silodosin Chemical compound N([C@@H](CC=1C=C(C=2N(CCCO)CCC=2C=1)C(N)=O)C)CCOC1=CC=CC=C1OCC(F)(F)F PNCPYILNMDWPEY-QGZVFWFLSA-N 0.000 title claims abstract description 35
- 229960004953 silodosin Drugs 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 239000000203 mixture Substances 0.000 title claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000003960 organic solvent Substances 0.000 claims abstract description 9
- 239000002775 capsule Substances 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 13
- 238000001035 drying Methods 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 2
- 238000013019 agitation Methods 0.000 claims 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 1
- 238000009835 boiling Methods 0.000 claims 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 1
- 238000001291 vacuum drying Methods 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 239000004141 Sodium laurylsulphate Substances 0.000 description 5
- 238000004455 differential thermal analysis Methods 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 229920000881 Modified starch Polymers 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000005755 formation reaction Methods 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010029216 Nervousness Diseases 0.000 description 2
- DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 229960002613 tamsulosin Drugs 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 206010007026 Calculus urethral Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010051482 Prostatomegaly Diseases 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- QPUMEZIFDXYGPG-UHFFFAOYSA-N piperazine 1H-pyrrole Chemical class N1CCNCC1.N1C=CC=C1 QPUMEZIFDXYGPG-UHFFFAOYSA-N 0.000 description 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
- 229960001289 prazosin Drugs 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000009160 urethral calculus Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 238000004457 water analysis Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to semihydrate crystal of silodosin, a preparation method thereof and a medicinal composition containing the semihydrate crystal. The semihydrate crystal is prepared by crystallizing under the combined action of an organic solvent and water. The crystal form of the semihydrate crystal is represented by an X-ray powder diffraction figure of the semihydrate crystal.
Description
Technical field
The present invention relates to silodosin or formula (I) 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoro ethoxy) phenoxy group] ethylamino-] propyl group]-semihydrate crystal, the preparation method of 1H-indoles-7-methane amide and comprise its pharmaceutical composition.
Background technology
Silodosin (silodosin), 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2, the 2-trifluoro ethoxy) phenoxy group] ethylamino-] propyl group]-1H-indoles-7-methane amide, be a kind of indoline-like compound of replacement, its molecular structural formula is as follows:
Silodosin is a kind of α
1-adrenoceptor antagonists, contraction has optionally restraining effect to the urethra smooth muscle, and be of great use be used for the treatment of per urethram tissue stop up relevant, urinate that the control nervous disorders is relevant, the urethral function obstruction relevant and by dysuric medical compounds due to prostatomegaly, urethrostenosis, urethral calculus, prostate cancer, nervous bladder, the disease of the lower urinary tract, it can not cause the hypopiesia of an intensive hypotensive activity or a straight property.Its selectively acting to urethra is higher 12 times than Prazosin respectively, and is higher 7.5 times than Tamsulosin; In addition, silodosin can obviously suppress the human prostate contraction that norepinephrine causes, drug effect and Tamsulosin are suitable, and stronger than piperazine azoles.
Silodosin has in U.S. Pat 5387603 in the treatment dysuric purposes relevant with benign prostatic hyperplasia with it and describes.The preparation method of silodosin is disclosed in the Chinese patent 200580037040.2.Chinese patent 03824796.8 has been described silodosin α, β, three kinds of crystal formations of γ and preparation method thereof first.
In view of the pharmacological properties of this compound, obtain that purity is good, stability preferably this compound be very important and significant.In addition, as activeconstituents, with addition of acceptable accessories or vehicle, preparation is used for the treatment of dysuric pharmaceutical preparation and does not appear in the newspapers as yet with silodosin semihydrate crystal.
Summary of the invention
The present invention has now developed a kind of formula (I) compound, 2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2, the 2-trifluoro ethoxy) phenoxy group] ethylamino-] propyl group]-1H-indoles-7-methane amide (silodosin) semihydrate crystal and preparation method, this method acquisition silodosin semihydrate can be very definite, that circulation ratio is fabulous crystal.This kind method has good stability, and is easy and simple to handle, cost is low and characteristics such as economic environmental protection.
More specifically, the present invention relates to formula (I) compound crystal, it characterizes with following x-ray diffractogram of powder, uses diffractometer to measure, and represents with spacing d, 2 θ angles, intensity:
The invention still further relates to the preparation method of formula (I) compound crystal, the method is characterized in that, is to obtain formula (I) compound crystal after preparation and the drying under organic solvent and the water acting in conjunction.
The invention still further relates to and comprise as the semihydrate crystal of the silodosin of activeconstituents and the drug regimen of one or more suitable inert non-toxic vehicle.In the pharmaceutical composition of the present invention, what can mention more especially is to be suitable for oral formulation, tablet, capsule.
The performance test of silodosin semihydrate
1, ultimate analysis
| Element | Test value (%) | Theoretical value (%) |
| C | 59.34 | 59.46 |
| H | 6.59 | 6.54 |
| N | 8.26 | 8.32 |
| F | 11.24 | 11.30 |
The result shows that test value is consistent with theoretical value.
2, thermal weight loss and differential thermal analysis
Get the sample for preparing by the inventive method and carry out thermal weight loss and differential thermal analysis.The sample for preparing of this law does not have weightlessness before 0 ℃ as a result, does not promptly contain planar water and volatile solvent in the sample, and 60～102 ℃ of weightlessness is about 2.1%, this with sample in contain 0.5 molecular crystal water the result be consistent (theoretical value 1.98%).Differential thermal analysis result shows: this product has endotherm(ic)peak between 80～90 ℃, contains crystal water or recrystallisation solvent in the interpret sample.
3, weight loss on drying and water analysis
To be dried to constant weight at 65 ℃ with the sample that the inventive method prepares, the weight that subtracts mistake is 1.95%, and measuring its water content according to the Ka Shi aquametry simultaneously is 1.93%, two kind of unanimity as a result, shows and only contains moisture in the sample, does not contain other solvents.
Comprehensive ultimate analysis, thermal weight loss and differential thermal analysis result can determine to contain in the sample 0.5 molecular crystal water.
Description of drawings
Fig. 1 is silodosin semihydrate X-ray diffraction in crystals figure, and described ordinate zou shows the intensity of X ray, represent with Kcps, X-coordinate be shown as 2 θ (°).
Fig. 2 is a silodosin semihydrate crystalline thermal weight loss (TG graphic representation), and described ordinate zou is shown as part by weight (%) expression, and X-coordinate is shown as temperature ℃.
Fig. 3 is the differential thermal analysis (DSC graphic representation) of the crystal formation of silodosin semihydrate, and described ordinate zou is shown as compensation power (mW/mg) expression, and X-coordinate is shown as temperature ℃.
Embodiment
Following embodiment is explanation content of the present invention better, but the invention is not restricted to following example.
Embodiment 1: the semihydrate crystalline preparation of silodosin
Get this product 1g with 2ml ethanol heating for dissolving after, remove by filter insolubles, stir and slowly in mother liquor, drip 30ml water to crystalline solid down and separate out fully, and continue to stir 30 minutes.Filter to collect the solid that obtains, to constant weight, obtain the 950mg crystal, purity 99.3% in following 50 ℃ of dryings of vacuum 12 hours.The gained crystal formation characterizes with following x-ray diffractogram of powder, uses diffractometer to measure, and represents with spacing d, 2 θ angles, intensity and intensity:
Embodiment 2: the semihydrate crystalline preparation of silodosin
Get this product 1g with 2ml ethyl acetate heating for dissolving after, remove by filter insolubles, stir slowly in mother liquor, to drip down and add water to solid and separate out, add 5ml water after solid is separated out, and continue to stir 0.5 hour.Filter to collect the solid that obtains, to constant weight, obtain the 930mg crystal, purity 99.5% in following 50 ℃ of dryings of vacuum 12 hours.
The gained crystal formation characterizes with following x-ray diffractogram of powder, uses diffractometer to measure, and represents with spacing d, 2 θ angles, intensity:
Embodiment 3: capsule 1
Prescription:
N.F,USP MANNITOL 66.5g
Pregelatinized Starch 30.0g
Magnesium Stearate 1.0g
Sodium lauryl sulphate 0.5g
According to above prescription, by comprising 1000 capsules of 2.0mg silodosin semihydrate crystal in the ordinary method preparation capsule.
Embodiment 4: capsule 2
Prescription:
Microcrystalline Cellulose 56.5g
Lactose 40.0g
Magnesium Stearate 0.5g
Sodium lauryl sulphate 1.0g
According to above prescription, by comprising 1000 capsules of 2.0mg silodosin semihydrate crystalline in the ordinary method preparation capsule.
Embodiment 5: capsule 3
Prescription:
Silodosin semihydrate crystal 4 .0g
Lactose 63.5g
Pregelatinized Starch 30.0g
Talcum powder 0.5g
Sodium lauryl sulphate 2.0g
According to above prescription, by comprising 1000 capsules of 4.0mg silodosin semihydrate crystalline in the ordinary method preparation capsule.
Embodiment 6: tablet 1
Prescription:
N.F,USP MANNITOL 59.0g
Pregelatinized Starch 30.0g
Low-substituted hydroxypropyl cellulose 5.0g
HPMC E50 2.0g
Magnesium Stearate 1.0g
Sodium lauryl sulphate 1.0g
According to above prescription, by comprising 1000 capsules of 2.0mg silodosin semihydrate crystalline in the ordinary method preparation tablet.
Embodiment 7: tablet 2
Prescription:
Silodosin semihydrate crystal 4 .0g
N.F,USP MANNITOL 56.0g
Pregelatinized Starch 30.0g
Low-substituted hydroxypropyl cellulose 5.0g
30 POVIDONE K 30 BP/USP 30 2.0g
Talcum powder 1.0g
Sodium lauryl sulphate 2.0g
According to above prescription, by comprising 1000 capsules of 4.0mg silodosin semihydrate crystalline in the ordinary method preparation tablet.
Claims (9)
1.2,3-dihydro-1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2, the 2-trifluoro ethoxy) phenoxy group] and ethylamino-] propyl group]-crystal of the compound shown in the formula (I) of 1H-indoles-7-methane amide semihydrate
Its crystal characteristic characterizes with following x-ray diffractogram of powder, uses diffractometer to measure, and represents with spacing d, 2 θ angles, intensity:
2. the preparation method of the formula of claim 1 (I) compound crystal is characterized in that, is obtaining formula (I) compound crystal after preparation and the drying under organic solvent and the water acting in conjunction.
3. organic solvent as claimed in claim 2 is characterized in that organic solvent is meant any solvent or the combination in methyl alcohol, ethanol, propyl alcohol, Virahol, ethyl acetate, acetone, methylene dichloride, chloroform, hexanaphthene, normal hexane, acetonitrile, tetrahydrofuran (THF) and the toluene.
4. as claimed in claim 3 under the acting in conjunction of organic solvent and water, it is characterized in that, be earlier under heating, to dissolve silodosin, under agitation again water droplet be added in the organic solution to solid and fully separate out the formula of preparing (I) compound crystal with organic solvent.
5. as claimed in claim 4ly earlier under heating, dissolve silodosin, it is characterized in that with organic solvent, Heating temperature be 15 ℃ to solvent boiling point; As claimed in claim 4 under agitation again water droplet being added in the organic solution to solid fully separated out, it is characterized in that, the dropping water yield is 1.0ml/min to 6.0ml/min, and dripping water is 1: 10～1: 100 with the volume of organic solvent ratio, and preferred volume ratio is 1: 20～1: 30.
6. formula (I) compound crystal that drying as claimed in claim 3 obtains is characterized in that drying mode is under the lucifuge condition, and 35～60 ℃ of vacuum-dryings are to constant weight.
7. one kind is used for the treatment of dysuric pharmaceutical composition, and it comprises as the claim 1 of activeconstituents described silodosin semihydrate crystal and acceptable accessories or vehicle.
8. pharmaceutical composition as claimed in claim 5 is characterized in that, described formulation is to be suitable for oral formulation.
It is 9. as claimed in claim 6 that to be suitable for oral formulation be tablet, capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010245337 CN102229557B (en) | 2010-08-05 | 2010-08-05 | Semihydrate crystal of silodosin, preparation method thereof and medicinal composition containing semihydrate crystal |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010245337 CN102229557B (en) | 2010-08-05 | 2010-08-05 | Semihydrate crystal of silodosin, preparation method thereof and medicinal composition containing semihydrate crystal |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102229557A true CN102229557A (en) | 2011-11-02 |
| CN102229557B CN102229557B (en) | 2013-03-27 |
Family
ID=44842178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010245337 Active CN102229557B (en) | 2010-08-05 | 2010-08-05 | Semihydrate crystal of silodosin, preparation method thereof and medicinal composition containing semihydrate crystal |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102229557B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1694867A (en) * | 2002-09-06 | 2005-11-09 | 橘生药品工业株式会社 | Crystal for oral solid drug and oral solid drug for dysuria treatment containing the same |
| CN101048376A (en) * | 2004-10-27 | 2007-10-03 | 橘生药品工业株式会社 | Indoline compound and process for producing the same |
| CN101412690A (en) * | 2008-12-01 | 2009-04-22 | 巢杰 | Medicinal acid addition salt of silodosin, and preparation and medicament use thereof |
-
2010
- 2010-08-05 CN CN 201010245337 patent/CN102229557B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1694867A (en) * | 2002-09-06 | 2005-11-09 | 橘生药品工业株式会社 | Crystal for oral solid drug and oral solid drug for dysuria treatment containing the same |
| CN101048376A (en) * | 2004-10-27 | 2007-10-03 | 橘生药品工业株式会社 | Indoline compound and process for producing the same |
| CN101412690A (en) * | 2008-12-01 | 2009-04-22 | 巢杰 | Medicinal acid addition salt of silodosin, and preparation and medicament use thereof |
Non-Patent Citations (2)
| Title |
|---|
| 《Neurourology and Urodynamics》 20100515 Tomonori Yamanishi et al. "Urodynamic Effects of Silodosin, a New a1A-Adrenoceptor Selective Antagonist, for the Treatment of Benign Prostatic Hyperplasia" 第558-562页 1-9 第29卷, * |
| TOMONORI YAMANISHI ET AL.: ""Urodynamic Effects of Silodosin, a New a1A-Adrenoceptor Selective Antagonist, for the Treatment of Benign Prostatic Hyperplasia"", 《NEUROUROLOGY AND URODYNAMICS》, vol. 29, 15 May 2010 (2010-05-15), pages 558 - 562 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102229557B (en) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI482768B (en) | The amorphous of a heterocyclic compound,the solid dispersoid consisting it,the preparation,and the process for preparing thereof | |
| US10377757B2 (en) | Crystal form of JAK inhibitor and preparation method thereof | |
| CN109311832A (en) | The pa of Vortioxetine not hydrochlorate and its crystal form | |
| EP2785691A1 (en) | Donepezil pamoate, preparation method and its use | |
| CN104844600B (en) | A kind of tadanafil compound, and combinations thereof | |
| EP1844017A1 (en) | An amorphous and three crystalline forms of rimonabant hydrochloride | |
| US10323035B2 (en) | Co-crystal of a CDK inhibitor and an MEK inhibitor and process of preparation thereof | |
| JP2021121645A (en) | CRYSTALLINE POLYMORPH OF 15β-HYDROXY-OSATERONE ACETATE | |
| TW201034664A (en) | Telmisartan acid addition salt | |
| CN106243180B (en) | Ethinyloestradiol novel crystal forms | |
| EP2952519A1 (en) | Protopanoxadiol derivative, preparation method thereof and application thereof | |
| CN110279689B (en) | Application of alpha-mangostin derivative in preparation of anti-therapeutic prostatic hyperplasia drugs | |
| WO2020233226A1 (en) | B crystal form of tetrahydrothienopyridine compound, preparation method therefor, composition and application | |
| WO2015192672A1 (en) | Benzofuran derivative, preparation method therefor, and application thereof | |
| CN104447682A (en) | Bilastine compound | |
| CN102229558B (en) | New silodosin crystal form delta, preparation method thereof and pharmaceutical composition containing the same | |
| CN102229557B (en) | Semihydrate crystal of silodosin, preparation method thereof and medicinal composition containing semihydrate crystal | |
| CN113943284B (en) | Pioglitazone hydrochloride gallic acid eutectic crystal and preparation method, composition and application thereof | |
| US10266523B2 (en) | Crystaline forms of N-[6-(cis-2,6-dimethylmorpholine-4-yl)pyridine-3-yl]-2-Methyl-4′-(trifluoromethoxy) [1,1′-biphenyl]-3-Methanamide monophosphate, and process of preparation thereof | |
| KR20210042041A (en) | Phenolamine Form B crystal, production method and composition and use thereof | |
| US20210015881A1 (en) | Agent exhibiting antiarrhythmic effect | |
| CN109422751A (en) | One kind has the degradation active compound of tyrosine protein kinase JAK3 | |
| CN111170959A (en) | Crystal form of macrolide compound, preparation method and application thereof | |
| CN113943283B (en) | Pioglitazone hydrochloride para aminobenzoic acid eutectic crystal and preparation, composition and application thereof | |
| CN106554376B (en) | Morphine derivatives crystal form II and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 210009 Room 1520, 15th Floor, Building A, Science and Technology Innovation Building, Nanjing Tech University, No. 5 Xin Model Road, Gulou District, Jiangsu Province Applicant after: Zou Qiaogen Address before: 8, building 26, 210009 Ma Jia street, Gulou District, Nanjing, Jiangsu Applicant before: Zou Qiaogen |
|
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: NANJING HEALTHNICE MEDICAL TECHNOLOGY Co.,Ltd. Assignor: Zou Qiaogen Contract record no.: 2012320000065 Denomination of invention: Semihydrate crystal of silodosin, preparation method thereof and medicinal composition containing semihydrate crystal License type: Exclusive License Open date: 20111102 Record date: 20120209 |
|
| ASS | Succession or assignment of patent right |
Owner name: NANJING HEALTHNICE MEDICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: ZOU QIAOGEN Effective date: 20121011 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20121011 Address after: 15, building 210009, A building, 5 new model road, Gulou District, Nanjing, Jiangsu Applicant after: NANJING HEALTHNICE MEDICAL TECHNOLOGY Co.,Ltd. Address before: 210009 Room 1520, 15th Floor, Building A, Science and Technology Innovation Building, Nanjing Tech University, No. 5 Xin Model Road, Gulou District, Jiangsu Province Applicant before: Zou Qiaogen |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: 210009, A15 building, 5 new model road, Jiangsu, Nanjing Patentee after: NANJING HEALTHNICE PHARMACEUTICAL TECHNOLOGY CO.,LTD. Address before: 15, building 210009, A building, 5 new model road, Gulou District, Nanjing, Jiangsu Patentee before: NANJING HEALTHNICE MEDICAL TECHNOLOGY Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20180514 Address after: 210009 A15 building, science and technology innovation building, 5 new model road, Nanjing, Jiangsu. Co-patentee after: NANJING HEALTHNICE PHARMACEUTICAL CO.,LTD. Patentee after: NANJING HEALTHNICE PHARMACEUTICAL TECHNOLOGY CO.,LTD. Address before: 210009 A15 building, science and technology innovation building, 5 new model road, Nanjing, Jiangsu. Patentee before: NANJING HEALTHNICE PHARMACEUTICAL TECHNOLOGY CO.,LTD. |
|
| TR01 | Transfer of patent right |